Cdk inhibitors
Patent Information
- Application Number
- TW114128940
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-05
- Filing Date
- 2021-05-05
- Publication Date
- 2026-11-01
- Estimated Expiration
- 2041-05-04
AI Technical Summary
There is a need for effective CDK4/6 inhibitors to treat proliferative lesions such as cancer, as existing treatments do not adequately address the regulation of the cell cycle and proliferation in various human tumors.
Development of compounds that inhibit the activity of cyclin-dependent kinases (CDKs) like CDK2, CDK4, and CDK6, including their medically acceptable salts and stereoisomers, which are used in pharmaceutical compositions to treat cancers including colorectal, breast, lung, prostate, glioblastoma, and leukemia.
The compounds demonstrate strong anti-proliferative activity and brain permeability, effectively inhibiting CDK4/6, reducing tumor growth, and enhancing the efficacy of other therapeutic agents in treating a range of cancers.
Abstract
Description
[Technical Field]
[0001] This invention relates to compounds or stereoisomers thereof that are CDK4 / 6 inhibitors that can be used to treat proliferative lesions such as cancer. [Previous Technology]
[0002] Cyclin-dependent kinases (CDKs) are a family of protein kinases first discovered for their role in regulating the cell cycle. They have been identified as playing a role in regulating a wide range of other biological functions, such as transcription, mRNA therapy, and neural cell differentiation.
[0003] CDKs are relatively small proteins with a molecular weight between approximately 34 and 40 kDa. They contain few kinase domains and are essentially inactive when not complexed with a class of regulatory proteins called cyclins. CDK levels remain relatively constant throughout the cell cycle, with the greatest regulation being transcription of cyclins, most notably through binding to cyclins.
[0004] Similar to all kinases, the active site, or ATP-binding site, of a CDK is located in the cleft between the small amino terminal lobe and the larger carboxyl terminal lobe. The structure of human CDK2 shows that CDKs have a modified ATP-binding site that can be regulated by cyclin binding. Phosphorylation at Thr 161 of the T loop in CDK-activated kinase (CAK) increases the activity of the complex. When not bound to cyclin, a flexible loop called the active loop or T loop blocks this cleft, and the positions of several key amino acid residues are not optimal for ATP binding. When bound to cyclin, two α-helices change position to allow ATP binding. One of them, the L12 helix preceding the T loop in the main sequence, becomes β-stranded and facilitates T loop rearrangement, thus no longer blocking the active site. The other α-helix, called the PSTAIRE helix, rearranges and helps change the position of key amino acid residues in the active site.
[0005] Therefore, only the cyclin-CDK complex possesses active kinase activity, and most known cyclin-CDK complexes are involved in cell cycle regulation. CDKs are widely distributed in all known eukaryotes, and their regulatory function in the cell cycle is evolutionarily conserved. For example, yeast cells can proliferate normally when the CDK gene has been replaced with a homologous human gene. CDKs exert their regulatory function through receptor phosphorylation on certain serine and tryptophan residues and the common sequence [S / T]PX[K / R], where S / T represents the target phosphorylation sites of serine (Ser) or threonine (Thr), P represents proline, X represents any amino acid, K represents lysine, and R represents arginine.
[0006] At least nine different CDKs exist in animal cells, four of which (CDK1, CDK2, CDK3, and CDK4) are directly involved in the regulation of the cell cycle. In mammalian cells, CDK1 and its binding partners cyclins A2 and B1 can independently drive the cell cycle. The cyclin-CDK complex in the early stages of the cell cycle can help activate the cyclin-CDK complex in the later stages.
[0007] The same CDK can form complexes with different cyclins to regulate different stages of the cell cycle. For example, CDK2 can form a complex with cyclin D or E to regulate the G1 stage; with cyclin A or E to regulate the S stage; and with cyclin A to regulate the G2 stage. Meanwhile, CDK4 and CDK6 can form complexes with cyclins D1, D2, and D3.
[0008] Highly homologous cyclin-dependent kinases (CDKs) CDK4 and CDK6 are key regulators of the transition between the G1 (growth) and S (DNA replication) phases of the cyclin D cell cycle via the restriction site R. CDK4 / 6 exert their effects through phosphorylation of retinoblastoma protein (pRb). Once phosphorylated, pRb loses its inhibitory effect on gene transcription that promotes entry into the S phase.
[0009] In contrast, the specific inhibition of CDK4 / 6 kinase activity by endogenous protein modulator p16INK4 or small molecule inhibitors leads to hypophosphorylated pRb and cell arrest at the G1 restriction point. As a major mechanism regulating the G1 restriction point, the pathways of these kinase regulation vary across a wide range of human tumors; therefore, inhibiting CDK4 / CDK6 in these tumors by preventing cell division has therapeutic benefits.
[0010] There is still a need to provide CDK4 / 6 inhibitors that can be used to treat proliferative lesions such as cancer. [Summary of the Invention]
[0011] The present invention discloses compounds that inhibit the activity of cyclin-dependent kinases (CDKs), such as CDK2, CDK4 and / or CDK6, as well as their medically acceptable salts or stereoisomers.
[0012] In one state, the present invention provides a compound or a medically acceptable salt thereof represented by the following structural formula:
[0012] . It was found that compound A not only actively inhibited CDK2, CDK4 and CDK6, but also exhibited strong anti-proliferative activity.
[0013] In another embodiment, the present invention provides a compound or a medically acceptable salt thereof represented by the following structural formula:
[0013] . It was found that compound B selectively inhibits CDK4 and also has excellent brain permeability.
[0014] It also provides pharmaceutical compositions comprising the compounds disclosed herein or their medically acceptable salts or stereoisomers and medically acceptable carriers.
[0015] This disclosure further provides a method of treating cancer in an individual with such need, comprising administering to the individual an effective amount of (1) the compound disclosed herein or a medically acceptable salt or stereoisomer thereof; or (2) a medically acceptable composition comprising the compound disclosed herein or a medically acceptable salt or stereoisomer thereof and a medically acceptable carrier. In some specific embodiments, the cancer is selected from the group consisting of colorectal cancer, breast cancer (such as hormone receptor-positive, HER2 / neu-negative advanced or metastatic breast cancer in postmenopausal women), lung cancer, prostate cancer, glioblastoma, mantle cell lymphoma, chronic myeloid leukemia, and acute myeloid leukemia.
[0016] In certain specific embodiments of the method of the present invention, the cancer can be treated by inhibiting the activity of cyclin-dependent kinases (CDKs) such as CDK2, CDK4 and / or CDK6.
[0017] In certain specific embodiments of the method of the present invention, the cancer is cancer of the bladder, breast, colon, kidney, epidermis, liver, lung, esophagus, gallbladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate or skin; hematopoietic malignant tumors of the lymphatic system; hematopoietic malignant tumors of the bone marrow system; follicular thyroid carcinoma; stromal tumors; tumors of the central or peripheral nervous system; melanoma; seminoma; teratoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; follicular thyroid carcinoma; or Kaposi's sarcoma.
[0018] In certain specific embodiments of the method of the present invention, the compounds disclosed herein are also administered together with any of the second therapeutic agents disclosed herein for treating the same cancer.
[0019] This disclosure also provides the use of the compounds disclosed herein, or their medically acceptable salts or stereoisomers, or medically acceptable compositions comprising such compounds or their medically acceptable salts or stereoisomers, in any of the methods of the present invention described above. In one specific embodiment, the use of the compounds disclosed herein, or their medically acceptable salts or stereoisomers, or medically acceptable compositions comprising such compounds or their medically acceptable salts or stereoisomers, in any of the methods of the present invention described above is provided. In another specific embodiment, the use of the compounds disclosed herein, or their medically acceptable salts or stereoisomers, or medically acceptable compositions comprising such compounds or their medically acceptable salts or stereoisomers, in the manufacture of pharmaceutical products for use in any of the methods of the present invention described above is provided.
Implementation Method
[0019] Cross-reference to related applications
[0020] This application claims priority to International Patent Application No. PCT / CN2020 / 088585, filed on May 5, 2020. The entire contents of the aforementioned application are incorporated herein by reference.
[0020] 1. Overview
[0021] The present invention provides a compound of the present invention or a medically acceptable salt thereof for treatment, such as cancer treatment.
[0022] The present invention also provides a pharmaceutical preparation comprising the compound of the present invention or a medically acceptable salt thereof, and a medically acceptable carrier, diluent or excipient.
[0023] This invention provides a compound of the invention or a medically acceptable salt thereof for the treatment of cancer. In particular, such cancers may be any cancers disclosed below, such as colorectal cancer, breast cancer (including ER+HER2 advanced or metastatic or recurrent breast cancer in adult women or postmenopausal women), lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantle cell lymphoma (MCL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML).
[0024] The present invention further provides a method for treating cancer in mammals selected from the group consisting of colorectal cancer, breast cancer (including ER+HER2 advanced or metastatic or recurrent breast cancer in adult or postmenopausal women), lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantle cell lymphoma (MCL), chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), the method comprising administering to the mammal in need of this treatment an effective amount of the compound of the present invention or a medically acceptable salt thereof.
[0025] Furthermore, the present invention provides the use of the compounds of the present invention or their medically acceptable salts in the manufacture of medicaments for treating cancer. In particular, the cancers are selected from the group consisting of colorectal cancer, breast cancer (including ER+HER2 advanced or metastatic or recurrent breast cancer in adult women or postmenopausal women), lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantle cell lymphoma, chronic myeloid leukemia, and acute myeloid leukemia.
[0026] Furthermore, the present invention provides a pharmaceutical preparation for treatment, comprising the compound of the present invention or a medically acceptable salt thereof, and a medically acceptable carrier, diluent, or excipient. The present invention also provides a pharmaceutical preparation for treating colorectal cancer, breast cancer (including ER+HER2 advanced, metastatic, or recurrent breast cancer in adult women or postmenopausal women), lung cancer, especially non-small cell lung cancer (NSCLC), prostate cancer, glioblastoma, mantle cell lymphoma, chronic myeloid leukemia, and acute myeloid leukemia, comprising the compound of the present invention or a medically acceptable salt thereof, and a medically acceptable carrier, diluent, or excipient.
[0027] The treatable disease indications and potential second therapeutic agents that can be used in combination therapy are further detailed in the following paragraphs.
[0028] It should be understood that any embodiment disclosed herein, including those disclosed only in one of the following paragraphs or only in the examples, may be combined with any one or more additional embodiments of the invention, unless expressly denied or otherwise unsuitable / inapplicable.
[0028] 2. Definition
[0029] The compounds disclosed herein may contain one or more centers of symmetry and therefore may exist in various stereoisomeric forms, such as mirror-image isomers and / or non-mirror-image isomers. For example, the compounds disclosed herein may be in the form of independent mirror-image isomers, non-mirror-image isomers or geometric isomers, or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched with one or more stereoisomers.
[0030] Mixtures of mirror-image isomers and mixtures of non-mirror-image isomers can be resolved into their mirror-image or stereoisomer compositions by known methods, such as chiral gas chromatography, chiral high-performance liquid chromatography, crystallization of the compound into a chiral salt complex, or crystallization of the compound in a chiral solvent. Mirror-image and non-mirror-image isomers can also be obtained by known asymmetric synthetic methods from pure non-mirror-image isomer intermediates or pure mirror-image isomer intermediates, reagents, and catalysts. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, ELStereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, SH Tables of Resolving Agents and Optical Resolutions p.268 (ELEliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
[0031] When a compound is designated by name or structure indicating a single mirror isomer, unless otherwise indicated, the compound is optically pure (also referred to as "mirror-isomer pure") of at least 60%, 70%, 80%, 90%, 99%, or 99.9%. Optical purity is the weight of the named or described mirror isomer in the mixture divided by the total weight of the mixture of the two mirror isomers.
[0032] When the stereochemistry of the disclosed compound is named or described by structure and the result of the naming or description covers more than one stereoisomer (e.g., in a non-mirror image pair of isomers), it should be understood that it includes one of the covered stereoisomers or any mixture of the covered stereoisomers. It should be further understood that the stereoisomer purity of the named or described stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight. In this case, the stereoisomer purity is determined by dividing the total weight of the mixture of stereoisomers covered by the name or structure by the total weight of the mixture of all stereoisomers.
[0033] When a geometric isomer is described by name or structure, it should be understood that the geometric isomer purity, by weight, is at least 60%, 70%, 80%, 90%, 99%, or 99.9%. Geometric isomer purity is determined by dividing the weight of the named or described geometric isomer in the mixture by the total weight of the two geometric isomers in the mixture.
[0034] A racemic mixture means 50% of one mirror-image isomer and 50% of the corresponding mirror-image isomer. This invention covers all mirror-image isomer pure, mirror-image isomer enriched, non-mirror-image isomer pure, non-mirror-image isomer enriched, racemic mixtures, and non-mirror-image isomer mixtures of the compounds of this invention.
[0035] The compounds disclosed herein may also include all isotopes of the atoms appearing in the intermediates or final compounds. An isotopic system includes atoms that have the same atomic number but different atomic masses. For example, the isotopic system of hydrogen includes tritium and deuterium.
[0036] It should be recognized that some variations in the abundance of natural isotopes occur in synthetic compounds, depending on the source of the chemical materials used in the synthesis. Therefore, the preparation of the compounds disclosed herein will inherently contain small amounts of deuterated isotope molecules. Despite this variation, the concentrations of naturally abundant stable hydrogen and carbon isotopes are small and immaterial compared to the degree of stable isotope substitution in the compounds of the present invention. See, for example, Wada, E et al., Seikagaku, 1994, 66:15; Gannes, LZ et al., Comp Biochem Physiol Mol Integr Physiol, 1998, 119:725.
[0037] The compounds disclosed herein can exist in various tautomer forms. The terms "tautomer" or "tautomerism" refer to two or more interconvertible compounds / substituents (e.g., single to double, triple to single, or vice versa) resulting from at least one formal migration of a hydrogen atom and at least one change of valence. Exemplary tautomerism includes ketones with enols, amides with amideimides, amides with amideimides, enamines with imides, and enamines with (different enamines). The teachings of this invention cover compounds in tautomer forms, including those not structurally described. Such isomers of all such compounds are explicitly included. If the tautomer of a compound is aromatic, then the compound is aromatic. Similarly, if the tautomer of a compound is heteroaryl, then the compound is heteroaryl.
[0038] In some cases, there are tautomer forms of the disclosed compounds, such as the tautomer structures shown below:
[0038]
[0039] It should be understood that when a compound is represented by a structural formula or designated by a chemical name herein, all other possible tautomer forms of the compound are covered by that structural formula.
[0040] The compounds of the present invention may exist in free form for therapeutic purposes, or, if appropriate, in the form of a medically acceptable salt.
[0041] In this document, the term "medically acceptable salt" means a salt that, within reasonable medical judgment, is suitable for contact with human and lower animal tissues without excessive toxicity, irritation, allergic reactions, etc., and in a proportionate benefit / risk ratio. Medically acceptable salts are known in the art to which this invention pertains; for example, Berge et al. disclose in detail medically acceptable salts in J. Pharmaceutical Sciences, 1977, 66, 1-19, which are incorporated herein by reference. Medically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of medically acceptable acid addition salts are salts formed by an amino group with an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or salts formed with an organic acid such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or salts formed by other known methods in the art to which this invention pertains, such as ion exchange. Other medically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, sulfite, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentylpropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucono-p-ethylhexanoate, glyceryl phosphate, gluconate, hemisulfate, heptaate, hexanoate, hydroiodate, 2-hydroxy-ethanesulfonate, lacturonate, lactate, lysinate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pyrate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, trimethylacetate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Salt systems derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts, and N+(C1-4 alkyl)4- salts. Representative alkali metal and alkaline earth metal salt systems include sodium, lithium, potassium, calcium, and magnesium salts. Furthermore, when appropriate, medically acceptable salt systems include those formed by the use of ammonium, quaternary ammonium, and amine cations as counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonates, and aryl sulfonates.
[0042] Such medically acceptable acid addition salts and their commonly used preparation methods are known in the technical field to which this invention pertains. See, for example, Stahl et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA / Wiley-VCH, 2002); Bighley et al., in “Encyclopedia of Pharmaceutical Technology.” Eds. Swarbrick and Boylan, Vol. 13, Marcel Dekker, Inc., New York, Basel, Hong Kong 1995, pp. 453-499; Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1): 1977.
[0043] The terms "composition" and "formulation" are used interchangeably.
[0044] "Individual" refers to mammals, preferably humans, but may also refer to animals that require veterinary treatment, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cattle, sheep, pigs, horses, etc.) and laboratory animals (e.g., rats, mice, guinea pigs, etc.).
[0045] The terms "administer," "administering," or "administration" refer to a method of introducing the compounds or components thereof of the present invention into an individual's body or body surface. Such methods include, but are not limited to, intra-articular (within a joint), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, oral, topical, intrathecal, inhalation, transdermal, and rectal administration. Administration techniques that can be used in conjunction with the agents and methods disclosed herein are found, for example, in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition, Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
[0046] The terms "treatment," "treat," and "treating" refer to reversing, alleviating, or inhibiting the progression of the disease disclosed herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have been developed or observed (i.e., therapeutic treatment). In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible individual before the onset of symptoms (i.e., prophylactic treatment) (e.g., given a medical history and / or given exposure to a pathogen). Treatment may also continue after symptoms have resolved, for example, to delay or prevent recurrence.
[0047] The terms “symptoms”, “diseases” and “lesions” are used interchangeably.
[0048] Generally, the effective amount of the compounds taught herein varies depending on various factors, such as the given drug or compound, pharmaceutical preparation, route of administration, type of disease or lesion, and attributes of the individual being treated or the host, but can still be conventionally determined by those skilled in the art to which the invention pertains. The effective amount of the compounds taught herein can be easily determined by conventional methods known to those skilled in the art to which the invention pertains.
[0049] The term "effective amount" means the amount that, when administered to an individual, results in a beneficial or desired effect, including clinical outcomes, such as inhibition, suppression, or reduction of symptoms of the individual's treated condition relative to a control. For example, an effective amount may be given in unit dosage form (e.g., 1 mg to about 50 g per day, or 1 mg to about 5 g per day).
[0050] "Therapeutic effective dose" refers to the detectable killing or inhibition of cancer cell growth or spread; tumor size or number; or other indicators of the level, stage, progression, or severity of cancer. The exact dose required will vary from person to person, depending on the individual's species, age and general health status; the severity of the disease; the specific anticancer agent; the mode of administration; combination therapy with other therapies; etc.
[0051] The general chemical terms used in the above formulas have their general meanings.
[0052] As used herein, "h" refers to one or more hours, "min" refers to one or more minutes, "Cdk" or "CDK" refers to cyclin-dependent kinase, "pRb" refers to retinoblastoma protein, "MCL" refers to mantle cell lymphoma, "AML" refers to acute myeloid leukemia, "CML" refers to chronic myeloid leukemia, "Boc" refers to N-tert-butoxycarbonyl, "EA" refers to ethyl acetate, "DCM" refers to dichloromethane, "DMSO" refers to dimethyl sulfoxide, "DMA" refers to dimethyl acetamide, "THF" refers to tetrahydrofuran, "Mt" refers to dichloromethane, "mt" refers to dimethyl sulfoxide, "mt" refers to dimethyl acetamide, "m" refers to dimethyl sulfoxide ... "BE" refers to methyl tributyl ether, "TEA" refers to triethylamine, "FBS" refers to fetal bovine serum, "PBS" refers to phosphate-buffered saline, "BSA" refers to bovine serum albumin, "RT" refers to room temperature, "mpk" means milligrams per kilogram, "po" means oral, "qd" means once daily, "HPLC" means high-performance liquid chromatography, "q2d" means a single dose every 2 days, "q2dx10" means 10 single doses every 2 days, "VSMC" refers to vascular smooth muscle cells, and "XRD" refers to X-ray diffraction.
[0052] 3. Compound
[0053] Another aspect of this disclosure relates to labeled compounds of the present invention (radiolabeled, fluorescently labeled, etc.), which can be used not only in imaging techniques but also in vivo and in vitro analyses for locating and quantifying CDKs in tissue samples, including those from humans, and for identifying CDK ligands by inhibiting the binding of the labeled compounds. Accordingly, this disclosure includes such labeled compounds.
[0054] This disclosure further includes isotopically labeled compounds of the present invention. An "isotopically labeled" or "radiolabeled" compound is a compound obtained by replacing one or more atoms of a compound of the present invention with another atom having an atomic mass or atomic number different from those typically found in nature (i.e., naturally occurring). Suitable radionuclides that can be incorporated into the compounds of the present invention include, but are not limited to, 2H (also written as D for deuterium), 3H (also written as T for tritium), 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 18F, 35S, 36Cl, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I, and 131I. The radionuclides in the radiolabeled compounds incorporated into the present invention also depend on the specific application of the radiolabeled compound.
[0055] The present invention may further include a method for synthesizing a radioactive isotope into the compounds of the present invention. The method for synthesizing a radioactive isotope into an organic compound is known in the art to which the invention pertains, and is a method readily recognized by those skilled in the art as applicable to the compounds of the present invention.
[0056] The labeled compounds of the present invention can be used in screening tests to identify / evaluate compounds. For example, the ability of a newly synthesized or identified labeled compound (i.e., the test compound) to bind to a CDK can be assessed by monitoring the concentration of the compound through the trace of the label. For example, the ability of the labeled test compound to reduce binding with another compound known to bind to a CDK (i.e., the standard compound) can be assessed. Accordingly, the ability of the test compound to compete with the standard compound for binding to a CDK is directly related to its binding affinity. Conversely, in other screening tests, the standard compound is labeled while the test compound is unlabeled. Accordingly, the concentration of the labeled standard compound is monitored to assess the competition between the standard compound and the test compound, and thus to determine the relative binding affinity of the test compound.
[0057] In one specific embodiment, the compound or a medically acceptable salt or stereoisomer thereof is provided, wherein one or more hydrogen atoms are replaced by deuterium.
[0057] 4. Treatable diseases and treatment methods
[0058] Certain compounds of the present invention are selective inhibitors of CDK2, CDK4 and / or CDK6, and are therefore used to treat diseases or lesions characterized by the ability to inhibit abnormal cell proliferation by reducing the activity of CDK-cyclin complexes including CDK2, CDK4 and / or CDK6.
[0059] In some specific embodiments, the compounds of the present invention selectively inhibit CDK4 / 6 relative to CDK2, and the ratio of the IC50 value of the latter (CDK2) to the former (CDK4 / 6) is at least about 10, 20, 50, 100, 200, 300, 400, 500, 800, 1,000, 2,000 or higher.
[0060] In some specific embodiments, the compounds of the present invention selectively inhibit CDK4 relative to CDK6, and the ratio of the IC50 values of the former (CDK6) to the latter (CDK4) is at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 50 or higher.
[0061] In some specific embodiments, the compounds of the present invention selectively inhibit CDK2 relative to CDK4, and the ratio of the IC50 value of the latter (CDK4) to the former (CDK2) is at least about 2, 5, 10, 15, 20, 40, 50, 60, 80, 100 or higher.
[0062] In certain specific embodiments, the compounds of the present invention inhibit CDK2 / 4 / 6 with similar IC50 values, for example, IC50 values within 10, 5, 3, or 2 times. Such compounds of the present invention can be used to treat cancers with amplified or increased expression of cyclin D1, E1, or E2.
[0063] CDK2 is the catalytic subunit of the CDK-cyclin complex, and its activity is restricted to the G1-S phase of the cell cycle, in which the cell produces proteins necessary for mitosis and replicates its DNA. CDK2 is complexed with either cyclin E or A. Cyclin E binds to CDK2 in the G1 phase, which is required for the transition from the G1 to the S phase. On the other hand, CDK2 that requires binding to cyclin A is required to proceed through the S phase.
[0064] Although CDK2 is largely absent in normally functioning cells, it is crucial for the abnormal growth process of cancer cells. Overexpression of cyclin E occurs in various tumor cells, causing cells to become dependent on both CDK2 and cyclin E. Abnormal cyclin E activity has been observed in breast cancer, lung cancer, colorectal cancer, gastric cancer, bone cancer, as well as leukemia and lymphoma. Similarly, abnormal cyclin A2 expression is associated with chromosomal instability and tumor proliferation, while inhibition leads to reduced tumor growth. Therefore, CDK2 and its cyclin binding partners represent potential therapeutic targets for novel cancer therapies. Preclinical models have shown initial success in limiting tumor growth, and reductions in the side effects of current chemotherapy drugs have also been observed.
[0065] For example, Caldon et al. (Mol Cancer Ther 11(7):1488-1499, 2012) reported that cyclin E2 is included in several gene signatures that predict the progression of tamoxifen-resistant or metastatic breast cancer, and that high expression of CycE2 is a characteristic of luminal B-type and HER2 subtype breast cancer, and strongly predicts shorter distant metastasis-free survival after endocrine therapy. Furthermore, tamoxifen-resistant (MCF-7 TAMR) breast cancer cells overexpress cyclin E2; and the expression of cyclin E1 or E2 in T-47D breast cancer confers acute anti-estrogen resistance, suggesting that overexpression of cyclin E contributes to the anti-estrogen resistance of tamoxifen-resistant cells. The proliferation of tamoxifen-resistant cells is inhibited by RNAi-mediated knockout of cyclin E1, cyclin E2, or CDK2. Furthermore, ectopic expression of cyclin E1 or E2 reduces sensitivity to CDK4 inhibition but not to CDK2 inhibition. Additionally, CDK2 inhibition in E-cyclin-overexpressing cells and tamoxifen-resistant cells restores sensitivity to either tamoxifen or CDK4 inhibition.
[0066] This data suggests that cyclin E2 overexpression is a potential mechanism for resistance to both endocrine therapy and CDK4 inhibition. CDK2 inhibitors can overcome this resistance, and because they effectively inhibit cyclin E1 and E2 overexpressing cells and enhance the efficacy of other therapies, they may have beneficial effects as part of combination therapy for endocrine-resistant diseases. Similarly, test compounds with potential inhibitory activity against both CDK2 and CDK4 are expected to be effective against cancer cells that are resistant to endocrine therapy or CDK4 inhibition, both in their presence and in their absence.
[0067] Therefore, in certain specific embodiments, the compounds of the present invention may have potential inhibitory effects on both CDK2 and CDK4 (e.g., IC50 levels of <10 nM, <5 nM, and <1 nM independently), and are therefore effective for treating tamoxifen-resistant or metastatic breast cancer, such as tamoxifen-resistant or metastatic breast cancer with CycE overexpression.
[0068] For example, the IC50 values of the compounds of the present invention for CDK2 / 4 / 6 can be measured using the methods disclosed in Examples 1 to 3 (incorporated herein by reference).
[0069] In particular, the compounds of the present invention can be used to treat cancer. In other specific embodiments, the compounds of the present invention can be used to treat chronic inflammatory diseases, such as arthritis and cystic fibrosis.
[0070] Therefore, in one embodiment, the present invention provides a method for treating cancer in mammals, particularly the cancers disclosed herein, including administering an effective amount of the compound of the present invention to a mammal in need of such treatment.
[0071] In the relevant context, the present invention relates to the use of the compounds of the present invention in the manufacture of a medicine for treating cancer, particularly the cancer disclosed herein.
[0072] In another related state, the compounds of the present invention can be used to manufacture medicines for treating cancer, particularly the cancers disclosed herein.
[0073] In another related embodiment, the present invention provides compounds of the present invention for use in the treatment of cancer, particularly the cancers disclosed herein.
[0074] According to any of the aforementioned embodiments of the present invention, the effects of CDK4 and CDK6 on the cell cycle can be partially modulated by pRb phosphorylation. Therefore, in any cancer type in which cells are proliferating and contain a functional, intact Rb1 gene encoding pRb, certain compounds of the present invention can inhibit pRb phosphorylation by inhibiting CDK4 / 6 activity, and thus inhibit cell proliferation and / or tumor growth.
[0075] Therefore, in certain specific embodiments, the compounds of the present invention can be used to treat pRb+ cancers in mammals, such as colorectal cancer, breast cancer, lung cancer, prostate cancer, chronic myeloid leukemia, acute myeloid leukemia (Fry et al., Mol. Cancer Ther. 3(11): 1427, 2004), mantle cell lymphoma (Marzec et al., Blood 108(5): 1744, 2006), ovarian cancer (Kim et al., Cancer Research 54: 605, 1994), pancreatic cancer (Schutte et al., Cancer Research 57: 3126, 1997), malignant melanoma and metastatic malignant melanoma (Maelandsmo et al., British Journal of Cancer 73: 909, 1996). It is also anticipated that the compounds of the present invention can be used to treat rhabdomyosarcoma (Saab et al., Mol. Cancer. Ther. 5(5): 1299, 2006) and multiple myeloma (Baughn et al., Cancer Res. 66(15): 7661, 2006) in mammals (e.g., humans), including relapsed refractory multiple myeloma.
[0076] Meanwhile, Zhang et al. (Nature dx.doi.org / 10.1038 / nature25015, 2017) reported that in mouse tumors and primary human pancreatic cancer samples, inhibition of CDK4 / 6 in vivo led to reduced phosphorylation and thus increased degradation of Cullin 3SPOP E3 ligase (via APC / CCdh1), which in turn led to increased PD-L1 content on the surface of tumor cells and reduced number of tumor-infiltrating lymphocytes (TILs). In other words, inhibition of CDK4 / 6 in vivo increases PD-L1 protein content and helps increase resistance to immune checkpoint therapies targeting PD-1 (programmed cell death protein 1) and PD-L1 (ligands for PD-1). On the other hand, in mouse tumor models, combination therapy with CDK4 / 6 inhibitors and anti-PD-1 immunotherapy enhanced tumor regression and significantly improved overall survival.
[0077] Therefore, in some specific embodiments, the compounds of the present invention can be used in combination with PD-1 / PD-L1 immune checkpoint inhibitors to enhance the efficacy against human cancers.
[0078] PD-1 and PD-L1 inhibitors that can be used in conjunction with the compounds of the present invention are known in the art to which this invention pertains. PD-1 inhibitors include monoclonal antibodies or antigen-binding fragments thereof that are specific to PD-1. Exemplary PD-1 inhibitors include pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). PD-L1 inhibitors include monoclonal antibodies or antigen-binding fragments thereof that are specific to PD-L1. Exemplary PD-L1 inhibitors include atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi).
[0079] Additional immune checkpoint inhibitors that can be used in combination with the compounds of the present invention to enhance the efficacy against human cancers include monoclonal antibodies or antigen-binding fragments thereof that are specific to CTLA-4, such as ipilimumab (Yervoy).
[0080] Other immune checkpoint inhibitors that can be used in combination with the compounds of the present invention to enhance the efficacy against human cancer include bispecific antibodies or antigen-binding fragments thereof that are specific to PD-1 and PD-L1, or monoclonal antibodies or antigen-binding fragments thereof that are specific to PD-1 and PD-L1 or PD-1 and CTLA-4, etc.
[0081] In certain embodiments, the compounds of the present invention may be co-used with Tyr kinase inhibitors, such as receptor Tyr kinase (RTK) inhibitors, to enhance efficacy against human cancers. Exemplary Tyr kinase inhibitors include ALK inhibitors (such as crizotinib, ceritinib, alectinib, and brigatinib), Bcr-Abl inhibitors (such as bosutinib, dasatinib, imatinib, nilotinib, and ponatinib), and BTK inhibitors (such as ibrutinib). c-Met inhibitors (such as crizotinib and cabozantinib), EGFR inhibitors (such as gefitinib, erlotinib, lapatinib, vandetanib, afatinib, and osimertinib), JAK inhibitors (such as ruxolitinib and tofacitinib), MEK1 / 2. Inhibitors (such as trametinib), PDGFR inhibitors (such as axitinib, gefitinib, imatinib, lenvatinib, nintedanib, pazopanib, regorafenib, sorafenib, sunitinib), and RET inhibitors (such as vandetanib). Src family kinase inhibitors (such as bosutinib, dasatinib, ponatinib, vandetanib) and VEGFR family inhibitors (such as axitinib, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib, sunitinib).
[0082] Other suitable kinase inhibitors and therapeutic cancer markers that can be used in combination with the test compound are disclosed in Bhullar et al., Molecular Cancer 17:48, 2018 (incorporated hereinforcingly by reference in their entirety).
[0083] Other additional RTK inhibitors include monoclonal antibodies and their antigen-binding fragments, including anti-EGFR mABs such as cetuximab (effective in treating, for example, lung cancer, colorectal cancer and head and neck cancer) and anti-HER2 mAbs such as trastuzumab (effective in treating, for example, breast cancer).
[0084] In some specific embodiments, the compounds of the present invention may be used in combination with hormone receptor signaling antagonists such as those previously disclosed in relation to breast cancer treatment.
[0085] Cancers that can be treated with the compounds of the present invention include: non-Hodgkin's lymphoma; malignant mesothelioma; non-small cell lung cancer; cholangiocarcinoma; soft tissue sarcoma; glioblastoma; (recurrent) brain tumors; brain metastases secondary to hormone receptor-positive breast cancer; non-small cell lung cancer; melanoma (including melanoma that is positive for cyclin D1); (recurrent or persistent) endometrial cancer; (recurrent or metastatic) head and neck squamous cell carcinoma (HNSCC); hepatocellular carcinoma; esophageal squamous cell carcinoma (SCC); esophageal adenocarcinoma (ADC); renal cell carcinoma and urinary tract epithelial cell carcinoma.
[0086] In certain specific embodiments, the treatable cancers include: bladder cancer, breast cancer, colon cancer, kidney cancer, epidermal cancer, liver cancer, lung cancer (including SCL and NSCLC), esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, gastric cancer, cervical cancer, thyroid cancer, nasal cancer, head and neck cancer, prostate cancer, or skin cancer; hematopoietic malignancies of the lymphatic system; hematopoietic malignancies of the bone marrow system; follicular thyroid carcinoma; stromal tumors; tumors of the central or peripheral nervous system; melanoma; familial melanoma; seminoma; teratoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; follicular thyroid carcinoma; Kaposi's sarcoma, squamous cell carcinoma, sarcoma; or tumors originating from the stroma.
[0087] In some specific embodiments, the hematopoietic malignant tumor of the lymphatic system is leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, piloblastic lymphoma, or Burkitt's lymphoma.
[0088] In some specific embodiments, the tumor of the central or peripheral nervous system is an astrocytoma, neuroblastoma, glioma or schwannoma.
[0089] In some specific embodiments, the cancer is small cell lung cancer, non-small cell lung cancer, pancreatic cancer, breast cancer, glioblastoma multiforme, T-cell ALL, and mantle cell lymphoma.
[0090] In some specific embodiments, the cancer is selected from the group consisting of: colorectal cancer, mantle cell lymphoma, breast cancer (including advanced, metastatic or recurrent breast cancer), pancreatic cancer, ovarian cancer, glioblastoma, acute myeloid leukemia and lung cancer, especially NSCLC.
[0091] In some specific embodiments, the cancer is NSCLC, pancreatic cancer, ovarian cancer or metastatic breast cancer, and the treatment includes administering a therapeutically effective amount of the compound of the present invention and gemcitabine hydrochloride to a mammal in need.
[0092] In some specific embodiments, the cancer is NSCLC, pancreatic cancer, ovarian cancer or metastatic breast cancer, and the pharmaceutical products containing the compounds of the present invention also include gemcitabine hydrochloride or are administered simultaneously, independently or sequentially with gemcitabine hydrochloride.
[0093] In certain specific embodiments, the compounds of the present invention may be used in combination with other agents used to treat NSCLC, pancreatic cancer, ovarian cancer, and metastatic breast cancer. For example, in the treatment of NSCLC, pancreatic cancer, ovarian cancer, and metastatic breast cancer, the compounds of the present invention may be used concurrently, independently, or sequentially with gemcitabine hydrochloride.
[0094] In some specific embodiments, the cancer is selected from the group consisting of colorectal cancer, glioblastoma, acute myeloid leukemia and lung cancer.
[0095] In some specific embodiments, the cancer is glioblastoma or astrocytoma, and the treatment involves using a therapeutically effective amount of the compound of the present invention in combination with temozolomide. The compound of the present invention is administered concurrently, alone, or sequentially with temozolomide.
[0095] Breast Cancer Treatment
[0096] In some specific embodiments, the compounds of the present invention can be used to treat breast cancer.
[0097] Breast cancer is a significant health burden worldwide, accounting for approximately 7% of cancer-related deaths in the United States in 2016. Of all breast cancers, approximately 75% are diagnosed as hormone receptor-positive (HR+) breast cancer, which expresses estrogen receptor (ER) and / or progesterone receptor (PgR) and typically depends on the ER signaling pathway for growth and survival. In other words, HR+ breast cancer utilizes the biological function of the ER pathway to promote breast cancer growth, development, and progression. Simultaneously, the dependence of HR+ breast cancer on ER signaling makes it a target for endocrine therapy agents that target the estrogen signaling pathway, such as aromatase inhibitors (AIs; including letrozole, anastrozole, and exemestane), selective ER modulators (temoxifen), and selective ER downregulators (fulvestrant).
[0098] Although endocrine therapy forms the backbone of treatment for HR+ breast cancer, its efficacy is limited by a high proportion of pre-existing de novo resistance and resistance acquired during treatment due to the existence of alternative survival or "escape" pathways. The ER pathway and several known escape pathways promote tumor growth by acting through the cyclin D-CDK4 / 6-CDK4 inhibitor (INK4)-retinoblastoma (Rb) pathway. Therefore, a combination targeting both the ER and cyclin D-CDK4 / 6-INK4-Rb pathways typically results in broader inhibition of tumor growth and prevention of escape pathway activation, thus preventing the development of endocrine therapy resistance. See Sammons et al., Current Cancer Drug Targets 17:637-649, 2017.
[0099] Therefore, in some specific embodiments, the breast cancer is pRb+ breast cancer. In some specific embodiments, the breast cancer is hormone receptor (HR) positive (e.g., estrogen receptor positive (ER+), progesterone receptor positive (PR+), or ER+PR+), HER2 / neu negative cancer, including HR+HER2- or ER+HER2- advanced or metastatic or recurrent breast cancer. In some specific embodiments, HR+HER2- or ER+HER2- advanced or metastatic or recurrent breast cancer is in adult women or postmenopausal women.
[0100] In some specific embodiments, the compounds of the present invention are used alone or in combination with aromatase inhibitors (which inhibit estrogen production) to treat HR-positive, HER2-negative advanced or metastatic or recurrent breast cancer. In some specific embodiments, the aromatase inhibitors transiently inactivate aromatase (such as anastrozole (ARIMIDEX®) and letrozole (FEMARA®)). In some specific embodiments, the aromatase inhibitors permanently inactivate aromatase (such as exemestane (AROMASIN®)).
[0101] In some specific embodiments, the compounds of the present invention are used in combination with compounds that interfere with the ability of estrogen to stimulate the growth of breast cancer cells. These compounds are, for example, selective estrogen receptor modulators (SERMs) that bind to estrogen receptors to prevent estrogen binding, such as tamoxifen (NOLVADEX®) and toremifene (FARESTON®). Tamoxifen has been used to treat HR+ breast cancer for over 30 years.
[0102] In some specific embodiments, the compounds of the present invention are used in combination with pure antiestrogens such as fulvestrant (FASLODEX®) which do not have estrogen agonist activity.
[0103] In some specific embodiments, HR-positive, HER2-negative advanced or metastatic or recurrent breast cancer is in postmenopausal women. In some specific embodiments, HR-positive, HER2-negative advanced or metastatic or recurrent breast cancer develops after treatment that modifies the patient's hormones (e.g., estrogen and / or progesterone), or worsens after treatment with another hormone.
[0104] In some embodiments, the compounds of the present invention are used in patients who are undergoing or have already undergone oophorectomy. In some embodiments, the oophorectomy is performed by oophorectomy or radiation therapy.
[0105] In certain embodiments, the compounds of the present invention are used in combination with compounds that temporarily inhibit ovarian function (e.g., the production of estrogen and / or progesterone). Such compounds include gonadotropin-releasing hormone (GnRH) agonists or luteinizing hormone-releasing hormone (LH-RH) agonists, including goserelin (ZOLADEX®) and leuprolide (LUPRON®).
[0106] In some specific embodiments, the compounds of the present invention are used in combination with compounds that inhibit CYP3A4, such as,Ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, telithromycin, chloramphenicol, ketoconazole, itraconazole, posaconazole, voriconazole, nefazodone, cobicistat, amiodarone, aprepitant, verapamil, diltiazem, erythromycin, fluconazole, miconazole zole, bergamottin, cimetidine, ciprofloxacin, cyclosporine, donedarone, fluvoxamine, imatinib, valerian, buprenorphine, caféfestol, cilostazol, fosaprepitant, gabapentin, lomitapide, orphenadrine, ranitidine, ranolazine, tacrolimus, ticagrelor, valproic acid The following are listed: [List of ingredients - likely related to vitamins and amino acids], amlodipine, cannabidiol, dithiocarbamate, mifepristone, norfloxacin, delavirdine, gestodene, mibefradil, star fruit, milk thistle, niacinamide, ginkgo biloba, piperine, isoniazid, and quercetin.
[0107] In some specific embodiments, the compounds of the present invention are used in combination with inhibitors of IGF-1 / IGF-2, such as monoclonal antibodies against IGF-1 / IGF-2 or antigen-binding fragments thereof. Exemplary anti-systems include xentuzumab, which is a humanized IgG1 mAb.
[0108] In some specific embodiments, the compounds of the present invention are used in combination with compounds that inhibit PI3K. It is believed that inhibiting PI3K reduces the levels of cyclin D1 and other G1-S cyclins, eliminates pRb phosphorylation, and inhibits the activation of the S-phase transcription program. Representative PI3K inhibitors used in combination with the compounds of the present invention include idelalisib, copanlisib, duvelisib, taselisib, perifosine, buparlisib, alpelisib, umbralisib, copanlisib, dactolisib, and voxtalisib.
[0109] In some specific embodiments, the mammal to be treated is a human, such as an adult woman with breast cancer (e.g., a postmenopausal or adult woman with advanced or metastatic or recurrent breast cancer that has progressed after treatment with hormone-enhancing drugs that have been administered to patients).
[0110] Furthermore, certain compounds of the present invention exhibit the advantageous property of being able to cross the blood-brain barrier. Such compounds are therefore able to penetrate the brain and can thus be used to treat primary and metastatic brain tumors in which cell lines are proliferating and contain a functional, intact Rb1 gene. Examples of such pRb+ brain tumors include glioblastoma, medulloblastoma, and astrocytoma (Lee et al., Science 235:1394, 1987).
[0111] Temozolomide is a cytotoxic DNA alkylating agent used to treat brain tumors, including glioblastoma and astrocytoma (Friedman et al., Clin. Cancer Res. 6(7): 2585-2597, 2000), including brain metastases of melanoma, breast cancer, and NSCLC (Siena et al., Annals of Oncology, doi: 10.1093 / annonc / mdp343, 2009). Temozolomide interacts with DNA, causing chemical modification / damage (Marchesi et al., Pharmacol. Res. 56(4): 275-287, 2007). Therefore, in some specific embodiments, the compounds of the present invention can be used in combination with temozolomide to treat primary and metastatic pRb+ brain tumors, such as glioblastoma and astrocytoma, for example, where such metastases originate from melanoma, breast cancer, or NSCLC.
[0111] 5. Pharmaceutical Compositions
[0112] The present invention provides a pharmaceutical composition comprising any of the compounds disclosed herein or a medically acceptable salt thereof, and one or more medically acceptable carriers or excipients.
[0113] "Medically acceptable excipients" and "medically acceptable carriers" refer to a substance that assists in the formation of an active agent and / or is administered to and / or absorbed by an individual, and may be included in the composition disclosed herein without causing significant toxic side effects to that individual. Non-limiting examples of medically acceptable carriers and excipients include water, NaCl, physiological saline, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (such as Ringer's solution), alcohols, oils, gels, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethyl cellulose, polyvinylpyrrolidone, and colorants, etc. Such formulations can be sterilized and, if necessary, mixed with adjuvants that will not adversely affect or interfere with the activity of the compounds provided herein, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt buffers that affect osmotic pressure, colorants, and / or aromatic substances. Those skilled in the art to which this invention pertains will recognize that other pharmaceutical carriers and excipients are suitable for use in combination with the disclosed compounds.
[0114] These compositions may further include one or more additional therapeutic agents as needed. Alternatively, the compounds of the present invention may be administered in combination with one or more other treatment regimens (e.g., Gleevec or other kinase inhibitors, interferon, bone marrow grafts, farnesyltransferase inhibitors, bisphosphonates, thalidomide, cancer vaccines, hormone therapy, antibodies, radiation, etc.) to patients in need. For example, the additional therapeutic agent used in combination with the compounds of the present invention or encapsulated in the pharmaceutical composition may be another one or more anticancer agents.
[0115] As disclosed herein, the composition of the present invention comprises the compounds of the present invention together with a medically acceptable carrier, which, as used herein, includes any and all solvents, diluents or other media, dispersants or suspending agents, surfactants, isotonics, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc., as appropriate for the desired specific dosage form. Remington's Pharmaceutical Sciences, 15th edition, EWMartin (Mack Publishing Co., Easton, Pa., 1975) discloses various carriers for formulating pharmaceutical compositions and known techniques for their preparation. Unless any conventional carrier medium is incompatible with the compounds of the present invention, such as by producing any undesirable biological effects or interacting with any other component in the pharmaceutical composition in a harmful manner, its use is considered to be within the scope of the present invention. Examples of materials that can be used as medically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered astragalus gum; malt; gelatin; talc; excipients such as cocoa butter and sulphurate; oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotropic saline; Ringer's solution; ethanol and phosphate buffer solutions; and other non-toxic, compatible lubricants such as sodium lauryl sulfate and magnesium stearate; as well as colorants, release agents, coating agents, sweeteners, flavorings and fragrances, preservatives, and antioxidants may also be present in the composition.
[0115] 6. Preparations
[0116] The present invention also covers a class of compositions comprising the active compounds of the present invention used in combination with one or more medically acceptable carriers and / or diluents and / or adjuvants (collectively referred to herein as “carrier” materials) and, if necessary, other active ingredients.
[0117] In some specific embodiments, the present invention provides a pharmaceutical preparation for treating cancer, particularly the cancers disclosed herein, which comprises the compounds of the present invention or their medically acceptable salts and medically acceptable carriers.
[0118] In some specific embodiments, the present invention provides a pharmaceutical preparation for treating cancers selected from the group consisting of colorectal cancer, mantle cell lymphoma, breast cancer (including ER+HER2- advanced or metastatic or recurrent breast cancer in adult women or postmenopausal women), glioblastoma, acute myeloid leukemia and lung cancer, especially NSCLC, comprising the compound of the present invention or a medically acceptable salt thereof and a medically acceptable carrier.
[0119] In some specific embodiments, the present invention provides a pharmaceutical preparation for treating glioblastoma or astrocytoma, comprising the compounds of the present invention, temozolomide, and a medically acceptable carrier.
[0120] In some specific embodiments, the present invention also provides pharmaceutical preparations comprising the compounds of the present invention or medically acceptable carriers thereof, temozolomide, and medically acceptable carriers, diluents, or excipients.
[0121] In some specific embodiments, the present invention provides a pharmaceutical preparation for treating NSCLC, pancreatic cancer, ovarian cancer or metastatic breast cancer (including ER+HER2- advanced or metastatic or recurrent breast cancer in adult women or postmenopausal women), which comprises the compounds of the present invention, gemcitabine hydrochloride and a medically acceptable carrier.
[0122] In some specific embodiments, the present invention also provides pharmaceutical preparations comprising the compounds of the present invention or medically acceptable carriers thereof, gemcitabine hydrochloride, and medically acceptable carriers, diluents or excipients.
[0123] The active compounds of the present invention can be administered by any suitable route, preferably in the form of a pharmaceutical composition suitable for such route, and the administered dose is effective for the intended treatment. The compounds and compositions of the present invention can be administered, for example, orally, via mucosal administration, external administration, rectal administration, pulmonary administration such as by inhalation spray, or via parenteral administration including intravascular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, intrasternal administration and infusion techniques, in dose-unit formulations containing conventionally acceptable carriers, adjuvants and mediators.
[0124] The pharmaceutically active compounds of the present invention can be used to treat patients, including humans and other mammals, according to conventional pharmaceutical methods.
[0125] For oral administration, the pharmaceutical composition may be in the form of, for example, tablets, capsules, suspensions, or liquids. Preferably, the pharmaceutical composition is formulated as a dosage unit containing a specific amount of the active ingredient.
[0126] Examples of such dosage units are tablets or capsules. For example, the appropriate daily dose for humans or other mammals may vary depending on the patient's condition and other factors, but can again be determined using conventional methods.
[0127] The dosage and dosing regimen of compounds used to treat diseases using the compounds and / or components of the present invention depend on a variety of factors, including an individual's age, weight, sex, and medical condition; the type of disease; the severity of the disease; the route and frequency of administration; and the specific compound used. Therefore, the dosing regimen can vary considerably, but can be routinely determined using standard methods. As previously mentioned, the daily dose may be given in a single administration or divided into 2, 3, 4, or more administrations.
[0128] For therapeutic purposes, the active compound of the present invention is typically used in combination with one or more adjuvants, excipients, or carriers suitable for the indicated route of administration. If administered orally, the compound may be mixed with lactose, sucrose, starch powder, cellulose esters of alkyl cellulose, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfuric acid, gelatin, gum arabic, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and subsequently formulated into tablets or capsules for administration. Such capsules or tablets may contain a controlled-release formulation, such as a dispersion of the active compound in hydroxypropyl methylcellulose.
[0129] In cases of dermatological conditions, it is preferable to apply the topical formulation of the compound of the present invention to the affected area two to four times daily. Formulations suitable for topical administration include liquid or semi-liquid formulations suitable for transdermal penetration (e.g., liniments, lotions, ointments, creams, or patches) and drops suitable for administration to the eyes, ears, or nose. For topical administration, the active ingredient may constitute 0.001% to 10% w / w of the formulation, for example, 1% to 2% by weight of the formulation. Although it may constitute up to 10% w / w of the formulation, it is preferably no more than 5% w / w, and more preferably 0.1% to 1%.
[0130] The compounds of the present invention can also be administered via transdermal devices. Preferably, transdermal administration will be carried out using a reservoir and a patch of the porous membrane type or solid matrix type. In each case, the active agent is continuously delivered from the reservoir or microcapsule through the membrane to an adhesive permeable to the active agent, which is in contact with the recipient's skin or mucous membrane. If the active agent is absorbed through the skin, a controlled and predetermined flow rate of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent can also function as a membrane. The oil phase of the emulsion of the present invention can be composed of known ingredients in a known manner.
[0131] Although the phase may contain only emulsifiers, it may contain at least one emulsifier and fats or oils, or both fats and oils. Preferably, the hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. It is also more preferably to include both oils and fats. The emulsifier, together with or without the stabilizer, constitutes a so-called emulsified wax, and the wax, together with the oils and fats, constitutes a so-called emulsified ointment matrix, which forms the oily dispersed phase of the cream preparation. The emulsifier and the emulsion stabilizer suitable for the formulations of the present invention include Tween 60, Span 80, cetearyl alcohol, myristone, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate, used alone, or in combination with waxes; or other materials known in the art to which the invention pertains.
[0132] The selection of the oil or fat suitable for this formulation is based on achieving the desired cosmetic properties, as the active compound has very low solubility in most oils that may be used in pharmaceutical emulsion formulations. Therefore, the cream is preferably a non-greasy, non-staining, and water-washable product with appropriate viscosity to avoid leakage from pipes or other containers. Straight-chain or branched-chain, mono- or dialkyl esters, such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut oil, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate, or blends of branched-chain esters can be used. These can be used alone or in combination, depending on the desired properties.
[0133] Alternatively, high-melting-point lipids such as white nephrite and / or liquid paraffin or other mineral oils may be used.
[0134] Formulations suitable for external administration to the eye also include eye drops, wherein the active ingredient is dissolved or suspended in a suitable carrier, particularly in an aqueous solvent of the active ingredient.
[0135] The active ingredient is preferably present in such formulations at a concentration of 0.5% to 20%, more preferably 0.5% to 10%, and particularly about 1.5% w / w.
[0136] Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injectable solutions or suspensions. Such solutions or suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned in oral formulations, or by using other suitable dispersants or wetting agents and suspending agents. These compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and / or various buffer solutions. Other adjuvants and administration methods are well known in the pharmaceutical field. The active ingredient may also be administered by injection as a component having a suitable carrier, including saline, dextran, or water, or having cyclodextrin (i.e., Captisol), solubilizing (i.e., propylene glycol), or microcellular solubilizing (i.e., Tween 80).
[0137] Sterile injectable formulations may also be sterile injectable solutions or suspensions, which are non-toxic, parenteral acceptable diluents or solvents, for example, solutions in 1,3-butanediol. Among acceptable media and dissolutions, water, Ringer's solution, and isotonic sodium chloride solution may be used. Furthermore, sterile, non-volatile oils are conventionally used as solvents or dispersion media. For this purpose, any non-irritating, non-volatile oil, including synthetic mono- or diglycerides, may be used. Additionally, fatty acids such as oleic acid may be used in injectable formulations.
[0138] For pulmonary administration, the pharmaceutical composition may be administered in aerosol form or via an inhaler, including dry powder aerosol.
[0139] A suppository for rectal administration of a drug may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter and polyethylene glycol, which is solid at room temperature but liquid at rectal temperature and thus dissolves in the rectum and releases the drug.
[0140] The pharmaceutical composition may undergo conventional pharmaceutical processes such as aseptic processing and / or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc. Tablets and pills may be additionally prepared with an enteric coating. Such compositions may also contain adjuvants, such as wetting agents, sweeteners, flavoring agents, and fragrances. The pharmaceutical compositions of the present invention comprise compounds of the formula disclosed herein or their medically acceptable salts; excipients selected from kinase inhibitors (small molecules, peptides, antibodies, etc.), immunosuppressants, anticancer agents, antiviral agents, anti-inflammatory agents, antifungal agents, antibiotics, or anti-angiogenic compounds; and any medically acceptable carrier, adjuvant, or mediator.
[0141] Other components of the present invention comprise compounds of the formula disclosed herein or medically acceptable salts thereof; and medically acceptable carriers, adjuvants, or mediators. Such components may, as desired, comprise one or more additional therapeutic agents, including, for example, kinase inhibitors (small molecules, peptides, antibodies, etc.), immunosuppressants, anticancer agents, antiviral agents, anti-inflammatory agents, antifungal agents, antibiotics, or anti-angiogenic compounds.
[0142] The term "medically acceptable carrier or adjuvant" means a carrier or adjuvant that can be administered to a patient together with the compound of the present invention, which does not destroy the pharmacological activity of the compound of the present invention, and is non-toxic when administered at a dose sufficient to deliver a therapeutic amount of the compound of the present invention. Medically acceptable carriers, adjuvants, and mediators that can be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants for pharmaceutical dosage forms, such as Tweens or other similar polymer delivery matrices, serum proteins such as human serum albumin, buffering substances such as phosphates, glycerol, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin. Cyclodextrins, such as u-cyclodextrin, p-cyclodextrin and γ-cyclodextrin or their chemically modified derivatives such as hydroxyalkyl cyclodextrin, including 2-hydroxypropyl cyclodextrin and 3-hydroxypropyl cyclodextrin, or other dissolved derivatives, may also be preferred for enhancing the delivery of compounds of the formula disclosed herein.
[0143] This pharmaceutical composition can be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, emulsions, aqueous suspensions, dispersions, and solutions. In the case of tablets for oral administration, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typical additions. For oral administration in capsule form, diluents that can be used include lactose and dried corn starch. When aqueous suspensions and / or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase and combined with emulsifiers and / or suspending agents.
[0144] If necessary, certain sweeteners, flavorings, and / or colorings may be added. The pharmaceutical composition may contain formulations using liposome or microencapsulation technology, various examples of which are known in the art to which this invention pertains.
[0145] This pharmaceutical composition can be administered via nasal aerosol or inhalation. Such compositions are prepared according to techniques known in the pharmaceutical formulation field and can be prepared as solutions in saline, using benzyl alcohol or other suitable preservatives, absorption enhancers to improve bioavailability, fluorocarbons and / or other solubilizers or dispersants, examples of which are also known in the technical field to which this invention pertains.
[0145] 7. Treatment Kit
[0146] One aspect of the invention relates to a kit for conveniently and efficiently carrying out the method or use according to the invention. Typically, a pharmaceutical package or kit comprises one or more containers filled with one or more pharmaceutical ingredients of the invention. Such kits are particularly suitable for delivering solid oral dosage forms such as tablets or capsules. Such kits preferably include multiple unit doses and may also include cards with doses arranged in order of their intended use. If desired, memory aids may be provided, for example, in the form of numbers, letters, or other markings, or with calendar inserts specifying the days on which the dose can be administered within a treatment schedule. Where necessary, such containers may be associated with notifications in the form prescribed by government authorities regulating the manufacture, use, or sale of pharmaceutical products, reflecting the approval of the manufacturing, use, or sale authority for the human administration of the pharmaceutical product.
[0147] The following representative examples contain important additional information, illustrations, and guidelines applicable to practicing the invention in various embodiments and their equivalents. Such examples are intended to help illustrate the invention, and are neither intended nor should be construed as limiting the scope of the invention. In fact, in addition to those shown and disclosed herein, various modifications and numerous further embodiments of the invention will become apparent to those skilled in the art upon review of the examples below and with reference to the scientific and patent literature cited herein, in addition to those examples below.
[0148] The contents of the cited references are incorporated herein by reference to help illustrate the state of the technical field to which the invention pertains.
[0149] Furthermore, for the purposes of this invention, the chemical elements are determined according to the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75th edition, inside cover. In addition, the general principles of organic chemistry, as well as specific functionalities and reactivity, are disclosed in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999 and "Organic Chemistry," Morrison & Boyd (3rd edition), the entire contents of which are incorporated herein by reference.
[0149] 8. Synthesis Scheme
[0150] Compounds of Formula I can be prepared by those skilled in the art following known techniques and processes within the art. More specifically, compounds of Formula I are prepared as detailed in the reaction formulas, methods, and examples described below. Those skilled in the art will recognize that individual steps in the following reaction formulas can be modified to provide compounds of Formula I. Reagents and starting materials are readily available to those skilled in the art. Unless otherwise specified, all substituent systems are as previously defined.
[0150] Example
[0150] Synthesis Example
[0150] Equipment Description
[0151] The 1H NMR spectra were recorded on a Bruker Ascend 400 spectrometer. Chemical shifts are expressed in parts per million (ppm, δ). Coupling constants are expressed in Hertz (Hz). Splitting modes describe apparent multiplicity and are designated as s (singleton), d (doublet), t (triplet), q (quartet), quintet, m (multiplet), and br (broad peak).
[0152] Analytical low-resolution mass spectrometry (MS) was recorded using a gradient flushing method on a Waters ACQUITY UPLC with an SQ detector using a Waters CORTECS C18+, 2.7 μm 4.6 × 30 mm spectrometer.
[0152] Solvent A: 0.1% formic acid (FA) in water
[0152] Solvent B: 0.1% FA in acetonitrile
[0152] From 5% ACN to 95% ACN within 1.0 minute, maintain for 1.0 minute.
[0152] Total 2.5 min; Flow rate: 1.8 mL / min; Column temperature: 40 degrees.
[0152] Intermediate
[0152] Intermediate 1
[0152]
[0152] Step 1
[0153] At 25°C, 236 mg of amino-2,4,6-trimethylbenzenesulfonate (1.1 mmol) was added to a solution of 4-benzyloxypyridine (185 mg, 998 μmol) in DCM (10 mL). The reaction mixture was stirred at 25°C for 14 hours. The mixture was concentrated under reduced pressure to give the desired crude product (400 mg) as a colorless oil. LC-MS: m / z 202[M+H]+.
[0153] Step 2
[0154] Cs₂CO₃ (192 mg, 1.4 mmol) and butyryn-2-one (94 mg, 1.4 mmol) were added to a solution of the above product (187 mg, 487 μmol) in DMF (10 mL). The reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2 × 25 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (with PE / EA = 10 / 1 extraction) to obtain the desired product (90 mg, 35% yield) as a yellow solid. LC-MS: m / z 267 [M+H]⁺.
[0154] Step 3
[0155] Butyllithium (43.3 mg, 675 μmol) was added dropwise to a solution of methyl(triphenyl)phosphonium bromide (241 mg, 675 μmol) in THF (10 mL) at -20 °C under N2. The reaction was stirred at -20 °C for 1 hour. Subsequently, 1-(5-benzyloxypyrazolo[1,5-a]pyridin-3-yl)acetone (90 mg, 338 μmol) in THF (15 mL) was added dropwise at -20 °C. The reaction mixture was stirred at 10 °C for 3 hours. The reaction mixture was quenched with MeOH (3 mL) and concentrated under reduced pressure. The residue was purified by preparative HPLC (with PE:EA = 1 / 1 extraction) to obtain the desired crude product (41 mg) as a yellow solid. LC-MS: m / z 265 [M+H]+.
[0155] Step 4
[0156] Pd / C (60 mg) was added to a solution of 5-benzyloxy-3-isopropenyl-pyrazolo[1,5-a]pyridine (600 mg, 2.3 mmol) in methanol (50 mL). The reaction mixture was stirred at 30 °C under H2 for 48 h. The reaction mixture was filtered and concentrated under reduced pressure to obtain the desired product (380 mg) as a yellow solid. LC-MS: m / z 177 [M+H]+.
[0156] Step 5
[0157] At 0°C and under N2, Tf2O (1.1 g, 4.1 mmol) was added to a solution of 3-isopropylpyrazolo[1,5-a]pyridine-5-ol (650 mg, 3.7 mmol) and DIPEA (410 mg, 4.1 mmol) in DCM (15 mL). The reaction mixture was stirred at 0°C for 2 h. The reaction mixture was washed with brine (15 mL) and dried over Na2SO4. The organic layer was filtered, and the filtrate was concentrated to obtain the desired product (1.1 g) as a colorless oil. LC-MS: m / z 309 [M+H]+.
[0157] Step 6
[0158] Pd(dppf)Cl2 (249 mg, 340 μmol) and KOAc (1.0 g, 10.2 mmol) were added to a solution of (3-isopropylpyrazolo[1,5-a]pyridin-5-yl)trifluoromethanesulfonate (1.1 g, 3.4 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)-1,3,2-dioxacyclopentane (1.3 g, 5.1 mmol) in diane (10 mL). The reaction mixture was stirred at 110 °C under N2 for 2 hours. The mixture was filtered and the filtrate was concentrated under reduced pressure to obtain the desired crude product (950 mg) as a dark solid. LC-MS: m / z 287 [M+H]+.
[0158] Step 7
[0159] To a solution of 3-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)pyrazolo[1,5-a]pyridine (950 mg, 3.3 mmol) and 2,4-dichloro-5-fluoropyrimidine (665 mg, 4.0 mmol) in H2O (1 mL) and 1,4-diane (15 mL), Na2CO3 (1.2 g, 10 mmol) and Pd(dppf)Cl2 (242 mg, 332 μmol) were added. The mixture was stirred at 110 °C for 6 h under N2. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (EA 0 to 50% PE / EA) to give the desired product (650 mg, 67% yield) as a yellow solid. LC-MS: m / z 291 [M+H]+.
[0159] Intermediate 2
[0159]
[0160] To a solution of 3-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)pyrazolo[1,5-a]pyridine (3.5 g, 12.2 mmol) and 2,4-dichloropyrimidine (2.7 g, 18.4 mmol) in water (3 mL) and 1,4-diane (60 mL), Pd(dppf)Cl2 (0.9 g, 1.2 mmol) and Na2CO3 (1.52 g, 14 mmol) were added. The reaction mixture was stirred at 110 °C under N2 for 6 h. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (PE with EA 0 to 50%) to give the desired product (2.1 g, 62% yield) as a yellow solid. LC-MS: m / z 273 [M+H]+.
[0160] Intermediate 3
[0160]
[0160] Step 1
[0161] At 0°C for 1 hour, HCl (1.5 L, 12 M in H2O) in 6.5 L of water was added dropwise to a mixture of 2,6-dichloro-3-nitropyridine-4-amine (1500 g, 7.2 mol) and iron powder (1933 g, 34.6 mmol) in ethanol (45 L) and water (3 L). The mixture was stirred at 95°C for 16 hours. The mixture was cooled to room temperature and then neutralized with sodium bicarbonate (solid) to pH=9. The mixture was filtered and washed with ethyl acetate (500 mL). The filtrate was concentrated to remove the solvent. The solution was then extracted with ethyl acetate (9 L). The combined organic layers were washed with brine (1 L), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give 1200 g of 2,6-dichloropyridine-3,4-diamine as a yellow solid.
[0161] Step 2
[0162] A solution of 2,6-dichloropyridine-3,4-diamine (1200 g, 6.74 mol) in triethoxymethane (3 L) was stirred at 140 °C for 28 hours under a nitrogen atmosphere. The reactants were concentrated. Formic acid (1.5 L) was added. The mixture was stirred at 120 °C for 2 hours. The solution was concentrated to obtain a residue, which was ground together with petroleum ether / ethyl acetate (1 / 1, 400 mL) to give 1360 g of 4,6-dichloro-1H-imidazo[4,5-c]pyridine as a yellow solid.
[0162] Step 3
[0163] A mixture of 4,6-dichloro-1H-imidazo[4,5-c]pyridine (1360 g, 5.8 mol), K₂CO₃ (5680 g, 17.4 mol), and 2-iodopropane (3951 g, 23.2 mol) in DMF (5 L) was stirred at 20 °C for 24 hours under a nitrogen atmosphere. Ethyl acetate (40 L) was added to the reaction mixture and the mixture was filtered. The filtrate was concentrated to obtain a residue, which was purified by a silicone column (petroleum ether / ethyl acetate, from 3:1 to 1:1) to give the desired product (710 g) as a yellow solid.
[0163] Step 4
[0164] CsF (510 mg, 3.4 mmol) was added to a mixture of 4,6-dichloro-1-isopropyl-imidazo[4,5-c]pyridine (250 mg, 1.1 mmol) in DMSO (10 mL), and the mixture was stirred at 140 °C for 1.5 h. The resulting mixture was poured into water (100 mL) and extracted with EA (3 × 30 mL). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated. The residue was purified by rapid column chromatography (80 g 200 to 300 mesh silica gel, PE / EA = 5 / 1 to 2 / 1) to give the desired product (210 mg, 75% yield) as a milky white solid. LC-MS: m / z 214.1 [M+H]+.
[0164] Step 5
[0165] To a solution of 6-chloro-4-fluoro-1-isopropylimidazo[4,5-c]pyridine (30 mg, 140 μmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentan-2-yl)-1,3,2-dioxacyclopentane (35.6 mg, 140 μmol) in diane (5 mL), potassium acetate (41.3 mg, 421 μmol) and cyclopentyl(diphenyl)phosphine dichloropalladium iron (15.4 mg, 21.1 μmol) were added. The mixture was degassed with N2 and stirred at 110 °C for 16 hours. The mixture was filtered through a diatomaceous earth mat. The filtrate was concentrated under reduced pressure to give the desired crude product (50 mg) as a black oil, which was used directly in the next step. LC-MS: m / z 224.2[M+H]+.
[0165] Step 6
[0166] Under a nitrogen atmosphere, Pd(dppf)Cl2 (24.6 mg, 33.6 μmol) and KOAc (66 mg, 672 μmol) were added to a solution of (4-fluoro-1-isopropyl-imidazo[4,5-c]pyridin-6-yl)boronic acid (50 mg, 224 μmol) and 2-chloro-5-fluoro-4-iodopyrimidine (53.9 mg, 224 μmol) in diane (3 mL). The mixture was degassed with nitrogen and stirred at 110 °C for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by rapid column chromatography using 0 to 60% ethyl acetate in petroleum ether to give the desired product (30 mg, 46% yield) as a white solid. LC-MS: m / z 292.1 [M+H]+.
[0166] Intermediate 4
[0166]
[0166] Step 1
[0167] To a solution of 5-bromo-2-nitropyridine (1 g, 4.9 mmol) and 1-isopropylpiperazine (631.6 mg, 4.9 mmol) in diane (40 mL), tris(benzylacetone)dipalladium(O) (451.1 mg, 492 μmol), (5-diphenylphosphino-9,9-dimethyl-dibenzopiperan-4-yl)-diphenylphosphine (570 mg, 985 μmol) and cesium carbonate (4.8 g, 14.8 mmol) were added. The reaction mixture was then stirred at 110 °C under N2 for 3 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography (extracted with 1-100% ethyl acetate in petroleum ether) to give the desired product as a white solid (850 mg, 68% yield). LC-MS: m / z 251.1 [M+H]+.
[0167] Step 2
[0168] Pd / C (412 mg, 10%) was added to a solution of 1-isopropyl-4-(6-nitro-3-pyridyl)piperazine (850 mg, 3.4 mmol) in ethanol (30 mL). The reaction mixture was then degassed three times with H₂ and stirred at 25 °C for 3 hours. The reaction mixture was filtered and subsequently washed with methanol (20 mL). The combined solvents were concentrated under reduced pressure to give the desired product (620 mg, 82% yield) as a brown solid. LC-MS: m / z 221.2 [M+H]⁺.
[0168] Intermediate 5
[0168]
[0168] Step 1
[0169] To a mixture of piperidine-2,4-dione (2.1 g, 18.5 mmol) and N-methylmethylamine (3.4 g, 74.2 mmol) in DCM (36 mL) and THF (18 mL), CH3COOH (10 mL) was added, and the resulting mixture was stirred at 25 °C for 3 h under a nitrogen atmosphere. Sodium triacetoxyborohydride (7.8 g, 37.1 mmol) was added to this mixture, and the mixture was stirred at 25 °C for 12 h under a nitrogen atmosphere. The reaction was quenched with water (50 mL) and concentrated under vacuum to remove DCM and THF. The mixture was extracted with DCM (3 × 100 mL). The organic solution was washed with brine (20 mL). The organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure to give the desired product (2.6 g), which was used in the next step without any purification. LC-MS: m / z 141.2 [M+H]+.
[0169] Step 2
[0170] Sodium borohydride (539 mg, 14.2 mmol) was added to a mixture of 4-(dimethylamino)-2,3-dihydro-1H-pyridin-6-one (1.0 g, 7.1 mmol) in methanol (15 mL), and the mixture was stirred at 25 °C for 12 h under a nitrogen atmosphere. The reaction was quenched with saturated NH4Cl aqueous solution (10 mL), followed by vacuum concentration to remove MeOH. The aqueous solution was purified by a reverse column (C18, 40 g) using (MeCN / water (0.1% NH4OH) = 1 / 10) to give the desired product (0.3 g, 32% yield) as a pale yellow solid. LC-MS: m / z 143.2 [M+H]+.
[0170] Step 3
[0171] A mixture of 4-(dimethylamino)piperidin-2-one (270 mg, 1.9 mmol), 5-iodopyridin-2-amine (1.0 g, 4.7 mmol), and potassium phosphate (1.2 g, 5.7 mmol) in diane (26 mL) was added with (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (162 mg, 1.1 mmol) and CuI (108 mg, 569 μmol). The mixture was stirred at 110 °C for 12 h under a nitrogen atmosphere. The reaction was filtered. The filtrate was concentrated under vacuum to give the residue, which was purified by a reverse column (C18, 20 g) using (MeCN / water (0.1% NH4OH) = 1 / 10) to give the desired product (272 mg, 61% yield) as a pale yellow solid. LC-MS: m / z 235.2[M+H]+.
[0171] Synthesis Example 1
[0171]
[0172] Cesium carbonate (125.1 mg, 384.1 μmol), tris(dimethylamino)piperidin-2-one (30 mg, 128 μmol), 5-(2-chloropyrimidin-4-yl)-3-isopropyl-pyrazolo[1,5-a]pyridine (38.4 mg, 140.8 μmol), and RuPhos (11.9 mg, 25.6 μmol) were added to a mixture of 1-(6-amino-3-pyridinyl)-4-(dibenzylacetone)dipalladium(O) (11.7 mg, 12.8 μmol) in diane (5 mL). The mixture was stirred at 110 °C for 4 h under a nitrogen atmosphere. The reaction mixture was extracted with EA (20 mL). The organic phase was washed with water (3 × 20 mL) and brine (3 × 20 mL) and dried over Na2SO4. The mixture was concentrated under reduced pressure and purified by rapid column chromatography (DCM / MeOH = 10:1) to give the desired product as a yellow solid (23.8 mg, 39% yield). LC-MS: m / z 471.2 [M+H]+.
[0172] Synthesis Examples 2 and 3
[0172]
[0173] N-[5-[4-(dimethylamino)-1-piperidinyl]-2-pyridinyl]-4-(3-isopropylpyrazolo[1,5-a]pyridin-5-yl)piperidin-2-amine (210 mg, 459.9 μmol) was chirally separated using a mobile phase (hexane / EtOH / DEA=60 / 40 / 0.1) with SFC (wavelength: UV 214 nm, column: CHIRALCEL OD-H 5.0 cm ID×25 cm L, flow rate: 60 mL / min) to obtain synthetic example 2 (44.2 mg, 21% yield) as a yellow solid (LC-MS: m / z 471.2 [M+H]+. ee value >99%) and synthetic example 3 (41 mg, 19% yield) as a yellow solid (LC-MS: m / z 471.2). 471.2[M+H]+. ee value = 97%).
[0173] Synthesis Example 4
[0173]
[0174] Pd2(dba)3 (47.1 mg, 51 μmol), RuPhos (47.9 mg, 102 μmol), and Cs2CO3 (502.6 mg, 1.5 mmol) were added to a solution of 5-(4-isopropylpiperazin-1-yl)pyridine-2-amine (124.6 mg, 565 μmol) and 6-(2-chloropyrimidin-4-yl)-4-fluoro-1-isopropyl-imidazo[4,5-c]pyridine (150 mg, 514 μmol) in diane (15 mL). The mixture was stirred at 110 °C under N2 for 3 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (using MeOH in DCM from 0 to 10% eluent) to give the desired product (107.2 mg, 43% yield) as a yellow solid. LC-MS: m / z 476.2 [M+H]+.
[0174] Biological Example 1. Detection of inhibition of CDK4 / cyclin D1
[0175] The CDK4 enzyme assay for determining IC50 was performed as follows. The Caliper microfluidic kinase assay was used to monitor the phosphorylation of peptide receptors by CDK4 / cyclin D1. The total reaction volume was 15 μL, containing buffer A (100 mM HEPES (pH 7.5), 0.1% BSA, 0.01% Triton X-100, 1 mM DTT, 10 mM MgCl2, 10 μM sodium orthovanadate, 10 μM β-glycerophosphate), 200 μM ATP, 1 nM CDK4 / cyclin D1 (Thermofisher, PR8064A), 1 μM FL-34 (5-FAM-RRRFRPASPLRGPPK), and a test compound suitable for dilution in DMSO. All components were added to a 384-well plate (Corning, 4514) and incubated at room temperature for 3 hours. The reaction was terminated by adding 15 μL of stop buffer (180 mM HEPES (pH 7.5), 20 mM EDTA, and Coating-3 reagent (PerkinElmer, 760050)). The disk was then loaded onto a Caliper EZ reader (EZ reader II, PerkinElmer, HD-4HYSG2772), and the reaction mixture, including the reactant and product, was aspirated onto a microfluidic chip for separation and detection. The IC50 value of the test compound was determined using Xlfit5 / GraphPad Prism 5 software, employing a 4-parameter sigmoid dose-response model to fit the inhibition curve.
[0175] Biological Example 2. Detection of inhibition of CDK6 / cyclin D3
[0176] The CDK6 enzyme assay for determining IC50 was performed as follows. The Caliper microfluidic kinase assay was used to monitor the phosphorylation of peptide receptors by CDK6 / cyclin D3. The total reaction volume was 15 μL, containing buffer A (100 mM HEPES (pH 7.5), 0.1% BSA, 0.01% Triton X-100, 1 mM DTT, 10 mM MgCl2, 10 μM sodium orthovanadate, 10 μM β-glycerophosphate), 300 μM ATP, 2 nM CDK6 / cyclin D3 (Carna, 04-107), 1 μM FL-34 (5-FAM-RRRFRPASPLRGPPK), and test compounds suitable for dilution in DMSO. All components were added to 384-well plates (Corning, 4514) and incubated at room temperature for 3 hours. The reaction was terminated by adding 15 μL of stop buffer (180 mM HEPES (pH 7.5), 20 mM EDTA, and Coating-3 reagent (PerkinElmer, 760050)). The disk was then loaded onto a Caliper EZ reader (EZ reader II, PerkinElmer, HD-4HYSG2772), and the reaction mixture, including the reactant and product, was aspirated onto a microfluidic chip for separation and detection. The IC50 value of the test compound was determined using Xlfit5 / GraphPad Prism 5 software, employing a 4-parameter sigmoid dose-response model to fit the inhibition curve.
[0176] Biological Example 3. Test for Inhibition of CDK2 / CyclinE1
[0177] The CDK2 enzyme assay for determining IC50 was performed as follows. The Caliper microfluidic kinase assay was used to monitor the phosphorylation of peptide receptors by CDK2 / cyclin E1. The total reaction volume was 15 μL, containing buffer A (100 mM HEPES (pH 7.5), 0.1% BSA, 0.01% Triton X-100, 1 mM DTT, 10 mM MgCl2, 10 μM sodium orthovanadate, 10 μM β-glycerophosphate), 100 μM ATP, 5 nM CDK2 / cyclin E1 (SignalChem, C29-18G), 5 μM FL-18 (5-FAM-QSPKKG-NH2), and a test compound suitable for dilution in DMSO. All components were added to a 384-well plate (Corning, 4514) and incubated at room temperature for 3 hours. The reaction was terminated by adding 15 μL of stop buffer (180 mM HEPES (pH 7.5), 20 mM EDTA, and Coating-3 reagent (PerkinElmer, 760050)). The disk was loaded onto a Caliper EZ reader (EZ reader II, PerkinElmer, HD-4HYSG2772), and the reaction mixture, including the reactant and product, was aspirated onto a microfluidic chip for separation and detection. The IC50 value of the test compound was determined using Xlfit5 / GraphPad Prism 5 software, employing a 4-parameter sigmoid dose-response model to fit the inhibition curve.
[0178] The IC50 values of each exemplary compound against CDK2, CDK4 and CDK6 are provided in the following synthetic examples. The IC50 values are indicated as "A", "B", "C" and "D", representing less than or equal to 10 nM; less than or equal to 100 nM; less than or equal to 1 μM; and greater than 1 μM, respectively.
[0178] Biological Example 4. Antiproliferative assay in T47D cells.
[0179] The T47D cell line is a human breast cancer cell line commonly used in biomedical research involving hormone expression in cancer cells. T47D cells differ from other human breast cancer cells in that their progesterone receptor (PR) is not regulated by estradiol, a hormone widely present in the cell itself. T47D cells have been used to study the effects of progesterone on breast cancer cells and the corresponding transcriptional regulation induced by introduced drugs. It has been noted that these cells exhibit extremely strong resistance to estrogen and anti-estrogens.
[0180] T47D breast cancer cells from the American Type Culture Collection (ATCC, HTB-133) were seeded at 3000 cells / well in 96-well plates and cultured at 37°C and 5% CO2 in RPMI 1640 medium (Gibco, 31800105) containing 10% fetal bovine serum (FBS, Biowest, FB-1058). After overnight culture, baseline values of samples from one plate were measured using Cyquant reagent (Invitrogen, C35011) following the manufacturer's recommendations. Cell lines were incubated at 37°C for 1 hour using the assay reagent, followed by fluorescence measurement at 485 nm excitation and 535 nm emission using a Spectra Max M5 (Molecular Devices, HD-4HYSG3196). Other plate lines were treated with compounds added using a 3-fold dilution protocol at ten concentrations ranging from 10 μM to 0.51 nM. On day 6 after the addition of the compound, Cyquant reagent was added, and fluorescence was measured using a Spectra Max M5. The IC50 of the compound's antiproliferative activity was determined using Xlfit5 / GraphPad Prism 5 software from the baseline minus the survival rate readout curve.
[0180] Biological Example 5. Inhibition of phosphorylation of retinal lymphoma protein (pRb) in T47D cells
[0181] T47D breast cancer cells from the American Center for Standard Culture Collection (ATCC, HTB-133) were seeded at 40,000 cells / well in 96-well plates and cultured in RPMI 1640 medium (Gibco, 31800105) containing 10% fetal bovine serum (FBS, Biowest, FB-1058). Cells were then allowed to adhere overnight at 37°C and 5% CO2. The following day, the compound was titrated using a 3-fold dilution protocol, with the highest concentration tested being 10 μM. After 24 hours of culture with the compound, cells were lysed in ice-cold lysis buffer containing a phosphate inhibitor mixture and 1 mM PMSF. Cell lysis buffer (50 μL / well) was then transferred to ELISA pans (pRb Ser807 / 811 ELISA kit, Cell Signaling, 13152; or pRb Ser780 ELISA kit, Cell Signaling, 13016). The pans were incubated overnight at 4°C with constant slow oscillation. After incubation, the pans were washed according to the manufacturer's instructions, and then 100 μL of reconstituted detection antibody was added to each well, and incubated at 37°C for 1 hour. After incubation, the pans were washed, and then 100 μL of reconstituted HRP-linked secondary antibody was added to each well, and incubated at 37°C for 30 minutes. After incubation, the pans were washed. Then, 100 μL of TMB receptor was added to each well, and incubated at 37°C for 10 minutes or at 25°C for 30 minutes. Finally, 100 μL of stop solution was added to each well and gently mixed for a few seconds. A 96-well luminescence mode disc was read using an Envision disc reader (PerkinElmer, 2104-0010). IC50 values were calculated using the 4-parameter S-mode dose-response model of the Xlfit5 / GraphPad Prism 5 software.
[0182] Cell data obtained from biological examples 4 and 5 are described in Table A below. IC50 values are indicated as "++++", which means less than or equal to 100 nM; "+++", which means less than or equal to 500 nM; "++", which means less than or equal to 1 μM; and "+", which means greater than 1 μM.
[0182]
Claims
1. A compound represented by the following structural formula: ; or a medically acceptable salt or stereoisomer thereof.
2. A compound represented by the following structural formula: .
3. A pharmaceutical composition comprising an effective amount of the compound as described in claim 1 or 2, or a medically acceptable salt thereof, and a medically acceptable carrier.
4. Use of a compound as described in claim 1 or 2, or a medically acceptable salt thereof, or a pharmaceutical composition as described in claim 3, in the preparation of a medicament for treating cancer, wherein, This cancer can be a cancer of the bladder, breast, colon, kidney, epidermis, liver, lung, esophagus, gallbladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate or skin; hematopoietic malignancies of the lymphatic system; hematopoietic malignancies of the bone marrow system; follicular thyroid carcinoma; stromal tumors; tumors of the central or peripheral nervous system; melanoma; seminoma; teratoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; or Kaposi's sarcoma.
5. Use of a compound as described in claim 1 or 2, or a medically acceptable salt thereof, or a pharmaceutical composition as described in claim 3, in the preparation of a medicament for inhibiting the activity of cyclin-dependent kinase (CDK) in an individual.
6. The use as described in claim 5, wherein, The individual has cancer.
7. The use as described in claim 5, wherein, This cancer includes cancers of the bladder, breast, colon, kidney, epidermis, liver, lung, esophagus, gallbladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate or skin, hematopoietic malignancies of the lymphatic system, hematopoietic malignancies of the bone marrow system, follicular thyroid carcinoma, stromal tumors, tumors of the central or peripheral nervous system, melanoma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, or Kaposi's sarcoma.
8. The use as described in claim 7, wherein, The hematopoietic malignancies of this lymphatic system include leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, piloblastic lymphoma, or Burkitt's lymphoma.
9. The use as described in claim 7, wherein the cancer is pRb+ breast cancer or hormone receptor (HR) positive, HER2 / neu negative cancer.
10. The use as described in claim 9, wherein, The cancer is estrogen receptor positive (ER+), progesterone receptor positive (PR+), or ER+PR+.
11. The use as described in claim 9, wherein, The cancer is advanced, metastatic, or recurrent breast cancer.
12. The use as described in claim 11, wherein, This type of breast cancer occurs in adult women or postmenopausal women.
13. The use as described in claim 6 further includes administering a second formulation of an aromatase inhibitor, a selective estrogen receptor modulator (SERM), a pure anti-estrogen without estrogen agonist activity, a compound that temporarily inhibits ovarian function, a compound that inhibits CCYP3A4, or a monoclonal antibody against IGF-1 / IGF-2 or an antigen-binding fragment thereof.
14. The use as described in claim 13, wherein, This compound, which temporarily suppresses ovarian function, inhibits the production of estrogen and / or progesterone.
15. The use as described in claim 13, wherein, The compounds that temporarily suppress ovarian function include gonadotropin-releasing hormone (GnRH) agonists or luteinizing hormone-releasing hormone (LH-RH) agonists.
16. The use as described in claim 6 further includes administering immune checkpoint inhibitors, receptor Tyr kinase inhibitors, and / or hormone receptor antagonists.
17. The use as described in claim 16, wherein, The immune checkpoint inhibitor includes a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor, and / or the hormone receptor antagonist includes an estrogen receptor antagonist.
Citation Information
Patent Citations
2,4-disubstituted pyrimidine derivative as CDK inhibitor and use thereof
EP3444246A1
Cdk inhibitors
TWI875756B
2-h-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
WO2016014904A1
Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
WO2016141881A1
CDK4 / 6 inhibitor and preparation method therefor and application thereof
WO2018045957A1
